Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

類似資料

• Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma
  著者:: Fowler, Nathan H, 等
  出版事項: (2014)
• Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
  著者:: Cheah, Chan Yoon, 等
  出版事項: (2015)
• Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
  著者:: Strati, Paolo, 等
  出版事項: (2021)
• Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
  著者:: Becnel, Melody R., 等
  出版事項: (2019)
• Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
  著者:: Giulio Cassanello, 等
  出版事項: (2024-09-01)